What is Nanobiotix?
Nanobiotix is a late-stage clinical biotechnology firm dedicated to developing disruptive, physics-based therapeutic solutions. Founded in 2003 and headquartered in Paris, France, with subsidiaries in the United States, Germany, Spain, and Switzerland, the company is committed to expanding the possibilities for human life by pushing scientific boundaries. Nanobiotix's innovative approach targets significant unmet needs in oncology, aiming to enhance the efficacy of existing treatments. The company has been publicly traded on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020, reflecting its established presence in the biopharmaceutical landscape.
How much funding has Nanobiotix raised?
Nanobiotix has raised a total of $281.3M across 4 funding rounds:
Debt
$11.3M
Stock Offering
$99M
Other Financing Round
$71M
Stock/Share Issuance
$100M
Debt (2020): $11.3M with participation from Bpifrance and HSBC
Stock Issuance/Offering (2020): $99M led by Undisclosed
Other Financing Round (2025): $71M supported by HealthCare Royalty Management
Stock/Share Issuance (2026): $100M, investors not publicly disclosed
Key Investors in Nanobiotix
Bpifrance
Bpifrance is a French public investment bank established in 2012, providing financing, guarantees, and equity to companies at all stages of development. They support innovation projects and international expansion, offering a wide range of products and services for entrepreneurs.
HSBC
HSBC is a global banking and financial services organization with a significant international network. Founded in 1865, it offers a comprehensive suite of banking products and services, facilitating international trade and capital flows across continents.
HealthCare Royalty Management
HealthCare Royalty Management is a specialized investment firm focused on the biopharmaceutical sector, providing capital solutions through royalty interests and tailored financing. They support innovation in life sciences by offering non-dilutive capital for companies advancing their products.
What's next for Nanobiotix?
The substantial enterprise-level capital infusion, including the recent strategic investment, positions Nanobiotix for accelerated growth and the advancement of its clinical pipeline. This backing is expected to fuel further research and development, potentially enabling the company to scale its operations and bring its novel therapies closer to market. The company's focus on physics-based approaches suggests a strategy aimed at creating differentiated, high-impact treatments. Nanobiotix's trajectory indicates a strong emphasis on innovation and a commitment to addressing critical healthcare challenges, with future developments likely centered on clinical trial progress and potential commercialization efforts.
See full Nanobiotix company page
